IGKV2D-29 and Parkinson disease: Istradefylline 3 [72], a moderately potent (pKi 7.44) and selective A2A antagonist that is structurally related to caffeine (Figure 2), is the only such ligand that is FDA-approved for clinical use, i.e., as a co-therapy with L-DOPA in PD treatment.